Literature DB >> 28783708

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Sarah F Andrews1, M Gordon Joyce2, Michael J Chambers2, Rebecca A Gillespie2, Masaru Kanekiyo2, Kwanyee Leung2, Eun Sung Yang2, Yaroslav Tsybovsky3, Adam K Wheatley4, Michelle C Crank2, Jeffrey C Boyington2, Madhu S Prabhakaran2, Sandeep R Narpala2, Xuejun Chen2, Robert T Bailer2, Grace Chen2, Emily Coates2, Peter D Kwong2, Richard A Koup2, John R Mascola2, Barney S Graham2, Julie E Ledgerwood2, Adrian B McDermott1.   

Abstract

Antigenic drift and shift of influenza strains underscore the need for broadly protective influenza vaccines. One strategy is to design immunogens that elicit B cell responses against conserved epitopes on the hemagglutinin (HA) stem. To better understand the elicitation of HA stem-targeted B cells to group 1 and group 2 influenza subtypes, we compared the memory B cell response to group 2 H7N9 and group 1 H5N1 vaccines in humans. Upon H7N9 vaccination, almost half of the HA stem-specific response recognized the group 1 and group 2 subtypes, whereas the response to H5N1 was largely group 1-specific. Immunoglobulin repertoire analysis of HA-specific B cells indicated that the H7N9 and H5N1 vaccines induced genetically similar cross-group HA stem-binding B cells, albeit at a much higher frequency upon H7N9 vaccination. These data suggest that a group 2-based stem immunogen could prove more effective than a group 1 immunogen at eliciting broad cross-group protection in humans.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2017        PMID: 28783708     DOI: 10.1126/sciimmunol.aan2676

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  37 in total

1.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

2.  Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.

Authors:  Seth J Zost; Nicholas C Wu; Scott E Hensley; Ian A Wilson
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

3.  A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Authors:  Takuya Yamamoto; Yuji Masuta; Masatoshi Momota; Masaru Kanekiyo; Tomohiro Kanuma; Shoukichi Takahama; Eiko Moriishi; Yasuhiro Yasutomi; Takashi Saito; Barney S Graham; Yoshimasa Takahashi; Ken J Ishii
Journal:  Int Immunol       Date:  2019-02-15       Impact factor: 4.823

4.  Dynamic Perspectives on the Search for a Universal Influenza Vaccine.

Authors:  Chadi M Saad-Roy; Adrian B McDermott; Bryan T Grenfell
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 5.  Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses?

Authors:  Daniel Stadlbauer; Raffael Nachbagauer; Philip Meade; Florian Krammer
Journal:  Front Med       Date:  2017-11-20       Impact factor: 4.592

6.  Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines.

Authors:  Sinthujan Jegaskanda; Sarah F Andrews; Adam K Wheatley; Jonathan W Yewdell; Adrian B McDermott; Kanta Subbarao
Journal:  JCI Insight       Date:  2019-11-14

7.  Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies.

Authors:  Claudia P Arevalo; Valerie Le Sage; Marcus J Bolton; Theresa Eilola; Jennifer E Jones; Karen A Kormuth; Eric Nturibi; Angel Balmaseda; Aubree Gordon; Seema S Lakdawala; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-06       Impact factor: 11.205

8.  Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus.

Authors:  Brenda L Tesini; Preshetha Kanagaiah; Jiong Wang; Megan Hahn; Jessica L Halliley; Francisco A Chaves; Phuong Q T Nguyen; Aitor Nogales; Marta L DeDiego; Christopher S Anderson; Ali H Ellebedy; Shirin Strohmeier; Florian Krammer; Hongmei Yang; Sanjukta Bandyopadhyay; Rafi Ahmed; John J Treanor; Luis Martinez-Sobrido; Hana Golding; Surender Khurana; Martin S Zand; David J Topham; Mark Y Sangster
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

9.  Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human.

Authors:  Seiya Yamayoshi; Mutsumi Ito; Ryuta Uraki; Tadahiro Sasaki; Kazuyoshi Ikuta; Yoshihiro Kawaoka
Journal:  J Infect       Date:  2017-12-14       Impact factor: 6.072

10.  Defining and Manipulating B Cell Immunodominance Hierarchies to Elicit Broadly Neutralizing Antibody Responses against Influenza Virus.

Authors:  Assaf Amitai; Maya Sangesland; Ralston M Barnes; Daniel Rohrer; Nils Lonberg; Daniel Lingwood; Arup K Chakraborty
Journal:  Cell Syst       Date:  2020-10-07       Impact factor: 10.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.